Gct1015-05/Gog-3024- A Phase 1B/2 Open-Label Trial Of Tisotumab Vedotin (Humax®-Tf-Adc) Monotherapy And In Combination With Other Agents In Subjects With Recurrent Or Stage Ivb Cervical Cancer
Posted Date: May 22, 2020
- Investigator: Amanda Jackson
- Specialties: Cancer, Cervical Cancer, Oncology
- Type of Study: Drug
The goal of this study is to establish the MTD and RP2D of tisotumab vedotin in combination in subjects with advanced cervical cancer
Criteria:
To Be Eligible: Must Have Squamous, Adenosquamous, Or Adenocarcinoma Of The Cervix, Measurable Disease, Ecog 0-1, Life Expectancy Of = 3 Months, No Signs Of Gi Obstruction, No Active Autoimmune Disorder Or Cardiovascular Disease, No Prior Malignancy With
Keywords:
Cervical Cancer
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com